Company / R&D Expense
Zivo Bioscience, Inc. R&D Expense History
FY2013-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$3.1M
FY2024
5-year range
$1.4M / $3.8M
FY2020-FY2024
Trend
+127.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $788,971 in FY2016 to $4M in FY2020.
Based on SEC 10-K filings.
$3M in FY2024 with a 10-year CAGR of +4.7%.
Improved from $2M to $3M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +17.1%
- 5-Year CAGR
- +6.3%
- 10-Year CAGR
- +4.7%
Key checks
Key Insights
- 5-year CAGR of +6.3%, indicating consistent growth.
- In FY2024, r&d expense increased 127.7% year-over-year.
- Peak r&d expense was recorded in FY2020.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -96.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.1M | +127.7% |
| FY2023 | $1.4M | -38.5% |
| FY2022 | $2.2M | +14.9% |
| FY2021 | $2.0M | -48.1% |
| FY2020 | $3.8M | +62.8% |
| FY2019 | $2.3M | +192.4% |
| FY2016 | $789.0K | -23.6% |
| FY2015 | $1.0M | -47.6% |
| FY2014 | $2.0M | +93.6% |
| FY2013 | $1.0M | +50.3% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026